Show notes

US Welcomes First Adalimumab Biosimilar, Amjevita

https://www.centerforbiosimilars.com/view/us-welcomes-first-adalimumab-biosimilar-amjevita 



Canada Approves High-Concentration Humira Biosimilar

https://www.centerforbiosimilars.com/view/canada-approves-high-concentration-humira-biosimilar 



Celltrion Submits BLA for Infliximab Biobetter

https://www.centerforbiosimilars.com/view/celltrion-submits-bla-for-infliximab-biobetter 



FDA Accepts BLA for Alvotech Ustekinumab Biosimilar

https://www.centerforbiosimilars.com/view/fda-accepts-bla-for-alvotech-ustekinumab-biosimilar 



Biosimilars Check-in: Approval in Saudi Arabia, Launch in Republic of Korea, Dr. Reddy’s Completes Study

https://www.centerforbiosimilars.com/view/biosimilars-check-in-approval-in-saudi-arabia-launch-in-republic-of-korea-dr-reddy-s-completes-study 



China's NMPA Approves Tocilizumab Biosimilar

https://www.centerforbiosimilars.com/view/china-s-nmpa-approves-tocilizumab-biosimilar  



US Welcomes First Adalimumab Biosimilar, Amjevita

https://www.centerforbiosimilars.com/view/us-welcomes-first-adalimumab-biosimilar-amjevita 



Study: Does Adalimumab Lose Effectiveness After Switching to a Biosimilar?

https://www.centerforbiosimilars.com/view/study-does-adalimumab-lose-effectiveness-after-switching-to-a-biosimilar- 



Phase 1 Trial for Alvotech Golimumab Biosimilar Begins

https://www.centerforbiosimilars.com/view/phase-1-trial-for-alvotech-golimumab-biosimilar-begins



Case Study: Treatment With Adalimumab Biosimilar Resolved Pediatric Scalp, Nail Psoriasis

https://www.centerforbiosimilars.com/view/case-study-treatment-with-adalimumab-biosimilar-resolved-pediatric-scalp-nail-psoriasis